Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;71(3-4):e12901.
doi: 10.1111/ijcp.12901. Epub 2017 Mar 20.

UK policy statements on testosterone deficiency

Geoffrey Hackett  1   2 , Michael Kirby  3   4 , David Edwards  5   6 , T Hugh Jones  7   8   9 , Jonathan Rees  10   11 , Asif Muneer  6   12
Affiliations

UK policy statements on testosterone deficiency

Geoffrey Hackett et al. Int J Clin Pract. 2017 Mar.

Abstract

To address widespread media and scientific concerns over the appropriate treatment of TDS with Testosterone Therapy (T Therapy), the Executive Committee of the British Society for Sexual Medicine developed eight consensus statements, based on current scientific evidence to address these controversial issues. These statements were in no-way designed to replace the published evidence-based guidelines on the subject developed by various professional organisations, but to provide specific answers to several current controversial issues. This review examined evidence from Medline, EMBASE and Cochrane searches on HG, T Therapy and cardiovascular safety from May 2005 to May 2015, which revealed 1714 articles, with 52 clinical trials and 32 placebo-controlled randomised controlled trials. The task force developed the following eight key statements.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of testosterone on multiple organ systems10
Figure 2
Figure 2
Trend for reduction in all‐cause mortality in T2DM appears greatest in men over 7533. Mortality in patients categorised by: Group A = normal testosterone; B= low testosterone untreated; C = low testosteron
Figure 3
Figure 3
Kaplan‐Meier curve depicting the all‐cause mortality among different propensity‐matched study groups46
See this image and copyright information in PMC

References

    1. Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR, AACE Reproductive Endocrinology Scientific Committee . American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr Pract. 2015;21():1066–1073. - PubMed
    1. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310():1829–1836. - PubMed
    1. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non‐fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE. 2014;9():e85805. - PMC - PubMed
    1. FDA testosterone products: drug safety communication—FDA investigating risk of cardiovascular events. http://www.fda.gov/safety/medwatch/safetyinfomation/safetyalertsforhuman.... Accessed February 2016.
    1. European Medicines Agency . No consistent evidence of heart attacks with testosterone medications. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/.... Accessed January 25, 2016.